EsoCap Technology
The Scientific Platform
EsoCap
owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first time.
The first Company to Enable Local Therapy in the Esophagus
This novel drug delivery system, designed to increase mucosal contact time and esophageal drug deposition, results in effective treatment of various esophageal diseases affecting 370 million patients, including eosinophilic esophagitis (EoE), GERD (gastrointestinal reflux disease), Barrett’s Syndrome, and esophageal cancer.
The EsoCap technology consists of a capsule containing a thin film loaded with a drug. Upon drinking the capsule from a specially designed drinking cup, the film unrolls and sticks to the patient’s esophageal mucosa, where it dissolves slowly while releasing the drug substance.
Our technology offers maximum flexibility, as multiple relevant drug substances, including biologics and further innovative compounds, can be incorporated into the thin film, making our drug delivery platform applicable to various clinical indications.
Dr. Werner Tschollar
Chairman of the Board
